Intrexon | XON - Operating Profit


Intrexon reported $-60.84M in Operating Profit for its fiscal quarter ending in June of 2024.





Operating Profit Change Date
Agenus USD 15.05M 656K Mar/2026
Alaunos Therapeutics USD -1.01M 175K Mar/2026
Amgen USD 4.61B 777M Jun/2026
Anika Therapeutics USD 646K 3.88M Dec/2025
Arrowhead Research USD -170.09M 28.83M Jun/2026
AstraZeneca USD 3.16B 3.95B Jun/2026
Bristol-Myers Squibb USD 299M 3.07B Jun/2026
Gilead Sciences USD 3.85B 1.17B Jun/2026
GlaxoSmithKline GBP 2.6B 312M Jun/2026
Heron Therapeutics USD 38K 3.83M Dec/2025
Incyte USD 700.4M 376.22M Jun/2026
Intrexon USD -60.84M 26.62M Jun/2024
Karyopharm Therapeutics USD -26.76M 8.92M Mar/2026
Ligand Pharmaceuticals USD 56.62M 3.7M Jun/2026
MacroGenics USD -33.44M 21.34M Mar/2026
MannKind USD -68.23M 8.76M Jun/2026
Merck USD 840M 2.72B Jun/2026
Novartis USD 4.75B 515M Jun/2026
Rigel Pharmaceuticals USD 14.06M 13.61M Sep/2024
Roche Holding CHF 11.46B 1.91B Jun/2026
Sangamo BioSciences USD -33.51M 12.77M Jun/2024
Thermo Fisher Scientific USD 2.18B 273M Jun/2026
Veracyte USD 23.96M 4.88M Jun/2026
Xencor USD -36.6M 41.26M Jun/2026